Copper transfer from Cu-Abeta to human serum albumin inhibits aggregation, radical production and reduces Abeta toxicity.
about
Multi-Target Directed Donepezil-Like Ligands for Alzheimer's DiseaseCopper chelator induced efficient episodic memory recovery in a non-transgenic Alzheimer's mouse modelMetals and cholesterol: two sides of the same coin in Alzheimer's disease pathology.The Case for Abandoning Therapeutic Chelation of Copper Ions in Alzheimer's DiseaseA prochelator activated by beta-secretase inhibits Abeta aggregation and suppresses copper-induced reactive oxygen species formation.X-ray and solution structures of Cu(II) GHK and Cu(II) DAHK complexes: influence on their redox properties.Development and validation of risk index for cognitive decline using blood-derived markersSpin hamiltonian parameters for Cu(II)-prion peptide complexes from L-band electron paramagnetic resonance spectroscopyModel peptides provide new insights into the role of histidine residues as potential ligands in human cellular copper acquisition via Ctr1.The human tripeptide GHK-Cu in prevention of oxidative stress and degenerative conditions of aging: implications for cognitive health.The elevated copper binding strength of amyloid-β aggregates allows the sequestration of copper from albumin: a pathway to accumulation of copper in senile plaquesInteractions of Zn(II) and Cu(II) ions with Alzheimer's amyloid-beta peptide. Metal ion binding, contribution to fibrillization and toxicity.Biochemistry of amyloid β-protein and amyloid deposits in Alzheimer disease.Biometals and their therapeutic implications in Alzheimer's disease.EPR Methods for Biological Cu(II): L-Band CW and NARS.Myricetin: a naturally occurring regulator of metal-induced amyloid-β aggregation and neurotoxicity.The Complexity of Sporadic Alzheimer's Disease Pathogenesis: The Role of RAGE as Therapeutic Target to Promote Neuroprotection by Inhibiting Neurovascular Dysfunction.Human serum albumin can regulate amyloid-β peptide fiber growth in the brain interstitium: implications for Alzheimer disease.A Trishistidine Pseudopeptide with Ability to Remove Both CuΙ and CuΙΙ from the Amyloid-β Peptide and to Stop the Associated ROS Formation.The Efficacy and Pharmacological Mechanism of Zn7MT3 to Protect against Alzheimer's Disease.Resistance of Cu(Aβ4-16) to Copper Capture by Metallothionein-3 Supports a Function for the Aβ4-42 Peptide as a Synaptic Cu(II) Scavenger.Copper(I) targeting in the Alzheimer's disease context: a first example using the biocompatible PTA ligand.A synthetic amino acid substitution of Tyr10 in Aβ peptide sequence yields a dominant negative variant in amyloidogenesis.N-terminal Cu Binding Motifs Xxx-Zzz-His (ATCUN) and Xxx-His and their derivatives: Chemistry, Biology and Medicinal Applications.A Functional Role for Aβ in Metal Homeostasis? N-Truncation and High-Affinity Copper Binding.Multifactorial Analysis of a Biomarker Pool for Alzheimer Disease Risk in a North Indian Population.Inhibition of Cu-amyloid-β by using bifunctional peptides with β-sheet breaker and chelator moieties.Use of curcumin in diagnosis, prevention, and treatment of Alzheimer's disease.Thermodynamic study of Cu2+ binding to the DAHK and GHK peptides by isothermal titration calorimetry (ITC) with the weaker competitor glycine
P2860
Q26744105-FDB54A6B-C928-4127-BBA3-5B7E7B3463B2Q28482435-790D5D7B-E01C-436D-933D-C3E382D506C3Q33646882-FFDB22F3-D261-43BD-BBA8-00CACBB1224EQ33755982-1E87F294-4CB0-4DC8-9851-3E3D8018FEF0Q33815126-04C998F7-A733-47BC-844C-DF1FE859A918Q33968513-D68DAC35-9659-4D94-9FE8-CC5BB6FEBFCEQ35106599-3F2348A8-5C74-4716-BF85-C3380F1E947FQ35147757-FA5EFC8A-9397-4681-A533-A0AE055F4732Q35636795-74D89FA1-8487-49D4-AF73-9AE3FBB775C7Q35986569-125BA177-93AB-416A-B32D-BA690B8CCDD9Q36553193-8C4A649C-7CB3-40C1-A88A-8CA151BD56E6Q37848098-77972E32-06A6-40E5-B3FF-1BD923F8F9ABQ38016898-E5C9AF8A-CBE8-4086-9900-5056A2CF79E3Q38263669-5D9D3C4D-B636-4648-BD82-DECE2570B337Q38691954-08C326A6-0626-4D12-A27C-030C9F01AA15Q39549160-6CBB061A-DF2B-4BD4-8181-7963ABBE6DFDQ41980641-B736E7D2-8474-4FC9-BF5B-6A36B930C2A1Q42322241-A3578C1C-1E1E-4787-B6F5-FFA62B1BA4ADQ46315694-754E9BFE-9E5A-4142-81C3-4EE532728B1BQ46331404-CE6C2EC1-EA8A-4735-A6FF-018CA280A627Q46540770-60CA0821-51E2-4D7E-B68B-23316AA09AC1Q46735574-06C80BEE-30E2-4FC5-AEBE-40C0496D6585Q48631163-C33508B7-40D0-4476-8FC2-DC11283E7D36Q50036711-6EAF0736-7803-4971-9F18-6D24F3C15774Q50578585-89CB9987-E64F-4E53-94A7-9C62E045A71FQ52600144-04F0E2A4-3A32-494E-B253-B714941DE063Q52623161-6F66C048-C4F5-4D84-952D-7882FEE2D6A2Q53397811-EAABD404-7E72-4477-B344-3936321C0F32Q57816817-E65E1023-A12C-456E-B35B-DBFE7E99C104
P2860
Copper transfer from Cu-Abeta to human serum albumin inhibits aggregation, radical production and reduces Abeta toxicity.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
Copper transfer from Cu-Abeta ...... on and reduces Abeta toxicity.
@en
Copper transfer from Cu-Abeta ...... on and reduces Abeta toxicity.
@nl
type
label
Copper transfer from Cu-Abeta ...... on and reduces Abeta toxicity.
@en
Copper transfer from Cu-Abeta ...... on and reduces Abeta toxicity.
@nl
prefLabel
Copper transfer from Cu-Abeta ...... on and reduces Abeta toxicity.
@en
Copper transfer from Cu-Abeta ...... on and reduces Abeta toxicity.
@nl
P2093
P50
P356
P1433
P1476
Copper transfer from Cu-Abeta ...... ion and reduces Abeta toxicity
@en
P2093
Anaïs Mockel
Cindy Figueroa
Emmanuelle Mothes
Maeva Vignes
Marie-Lise Maddelein
P304
P356
10.1002/CBIC.200900474
P577
2010-01-01T00:00:00Z